Veeva Summit 2019: How AI and Customer-First Strategies Help Marketers Stay Ahead of the Curve

Posted by Omer Hancer on Wed, May 22, 2019

Today, successful pharma outreach requires a customer-first mindset. This includes personalizing both content and channels, sending content at the right time and in the right channel to match customers’ levels of interest, adapting to physician reactions and humanizing AI sales and marketing suggestions for the rep so they understand why a suggested next best action is made. According to ZS research, personalization has resulted in a 20% increase in open rates for both marketing and rep-triggered emails and up to a 30% uplift in impactable sales.


>
Read More

Intelligent Process Automation: Starting is Easy, Scaling is a Different Ball Game

Posted by Vishal Kabra on Thu, May 09, 2019

Satish Jha co-wrote this blog post with Vishal Kabra 

Today, there is no denying that when it comes to increasing efficiency, reducing cost and offering a better customer experience, Intelligent Process Automation (IPA) is a go-to strategy for businesses, and pharma is no exception. IPA promises that it can free up people to do more value-added work and play more strategic roles within their organizations. At a fundamental level, IPA is an emerging set of new technologies that include robotic process automation (RPA), conversational AI and machine learning to mimic activities carried out by humans. With the evolution in IPA technologies and the broad applicability of such automation, IPA continues to be a buzzword in every industry. Given the many benefits and possibilities, it’s understandable why organizations are jumping onto the IPA bandwagon.

However, most organizations aren’t succeeding at scaling intelligent process automation.


>
Read More

Has AI Reached Peak Hype?

Posted by Arun Shastri on Wed, May 08, 2019

Pratap Khedkar co-wrote this blog post with Arun Shastri.

At The Wall Street Journal Health Forum, held in Washington D.C. on April 30, Novartis Chief Executive Vas Narasimhan called artificial intelligence “another tool in the toolbox.” This viewpoint diverges from recent notions that AI is a critical capability that’s going to change the way that pharma companies do business. In fact, industry experts have hoped that the dwindling return on investments for R&D (the current 3% ROI is predicted to hit 0% by 2020) could be reversed by employing AI-based technologies in drug discovery. There are more than 100 AI startups in this field that have received generous investments from venture capital. Yet, IBM has discontinued sales of its Watson AI system for drug discovery.


>
Read More

Technology, Patient Centricity and Disruption Remain Top of Mind for Health System Execs

Posted by Pratap Khedkar on Thu, May 02, 2019

I recently joined more than 4,000 attendees at the Becker's Hospital Review 10th Annual Meeting, held in Chicago in early April, to learn about the most pressing issues in the hospital and health system arena from a deep bench of industry experts. Interesting insights emerged across three of the critical themes that the healthcare industry is contending with, which got me thinking:


>
Read More

A New Delivery System for Next-Generation Cell and Gene Therapies

Posted by Maria Whitman on Thu, Apr 25, 2019

Kris Elverum of Turnstone Biologics co-wrote this blog post with Maria Whitman.

The evolution of medicines from small molecules to proteins has greatly advanced patient care, and up until now, our system of therapeutic delivery in the U.S. commercial system has been built with these therapeutics in mind. The next generation of cellular and gene therapies holds tremendous promise for patients, but only if the existing delivery system is revamped. There’s a real risk that most patients won’t benefit from these therapies as stakeholders struggle to find successful business models. In a recent article for Nature’s Gene Therapy, my industry colleague, Kris Elverum, and I take a critical look at the U.S. system and outline what needs to change to make approved cell and gene therapies accessible to patients.


>
Read More